Paper Details

  1. Home
  2. Paper Details

Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B.

Author: BansalSanjay, DanielJames F, KansuAydan, KellyDeirdre, MartinCarmen, Mieli-VerganiGiorgina, TizzardSarah, VerganiDiego, WirthStefan, ZhouJulian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A randomized controlled trial showed that antiviral therapy in children and adolescents with immune-tolerant chronic hepatitis B was effective and safe, with promising results for improving liver function and reducing viral load.
Paper Details　
Original Abstract of the Article :
Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades. On the basis of promising results of a pilot stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33720089

データ提供：米国国立医学図書館（NLM）

A New Strategy for Treating Chronic Hepatitis B in Children

This study ventures into the challenging realm of chronic hepatitis B (CHB) in children, a condition that can have long-term consequences for their health. Imagine a young desert traveler who has been exposed to a virus that can affect their well-being. This study explores a new approach to protecting these vulnerable individuals.

Antiviral Therapy for Immune-Tolerant CHB

The study evaluated the efficacy and safety of antiviral therapy using peginterferon alfa-2a plus lamivudine or entecavir in children with immune-tolerant CHB. The results showed that antiviral therapy was effective in reducing viral load and improving liver function in these children. This is like finding a vaccine that can protect the young traveler from the harmful effects of the virus, allowing them to navigate their journey safely.

Hope for Children with CHB

This research provides valuable information for clinicians who treat children with CHB, offering a safe and effective treatment option. The study underscores the importance of early intervention and the potential for improving long-term outcomes for these children. Like a desert oasis that provides sustenance and shelter, antiviral therapy can provide essential support for children facing the challenges of CHB.

Dr.Camel's Conclusion

This study offers a promising new approach for treating chronic hepatitis B in children, highlighting the importance of early intervention and the potential for improving long-term outcomes for these vulnerable individuals. It underscores the need for continued research to develop even better treatments and to improve the lives of children facing the challenges of this chronic condition.
Date :
  1. Date Completed 2021-10-14
  2. Date Revised 2023-08-22
Further Info :

Pubmed ID

33720089

DOI: Digital Object Identifier

00005176-202108000-00007

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.